Influenza A virus H5N1 vaccine - Novavax

Drug Profile

Influenza A virus H5N1 vaccine - Novavax

Alternative Names: H5N1 Clade 2 VLP influenza virus vaccine - Novavax; H5N1 Virus-Like Particle (VLP) Influenza vaccine (recombinant) - Novavax; H5N1 virus-like particle pandemic influenza vaccine - Novavax

Latest Information Update: 17 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novavax
  • Developer Novavax; University of Hong Kong
  • Class Influenza A virus H5N1 vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H5N1 subtype

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention) in USA (IM, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype(Prevention) in Hong Kong (IM, Injection)
  • 23 Sep 2014 BARDA modifies its contract with Novavax and awards an option period for Influenza-A virus H5N1 subtype vaccine development until September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top